Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Miyazaki
Clinical trial register · Japan

Clinical Trials in Miyazaki, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca4 AbbVie3 PharmaEssentia2 Sun Pharmaceutical Industries Limited2 Eli Lilly and Company2
Site location
Fukuoka551 Nagoya517 Sapporo398 Tokyo369 Osaka348
All 926 locations
Target enrolment
to

Trials with a site in Miyazaki

36 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
Takeda
Phase 3
324
Chiba, Toon-shi, Kobe, Hitachi, Tsu, Miyazaki, Bunkyo-Ku, Chuo-shi
2026-09-10
Recruiting
AstraZeneca
Phase 3
600
Asahikawa-shi, Kamakura-shi, Kashiwa-shi, Kobe, Komoro, Kumamoto, Kyoto, Miyazaki
2026-07-08
Recruiting
AstraZeneca
Phase 3
1,200
Asahikawa-shi, Chūōku, Kamakura-shi, Koga-shi, Kumamoto, Mitaka-shi, Mito, Miyazaki
2026-07-06
Recruiting
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
NCT07146906Immunoglobulin A Nephropathy (IgAN)
DrugZigakibart
Novartis Pharmaceuticals
Phase 2
32
Kawasaki, Miyazaki
2026-03-26
Recruiting
Eli Lilly and Company
Phase 3
900
Chiba, Chūōku, Kitakyushu-Shi, Miyazaki, Nagareyama, Ōita, Saitama, Sashima
2026-02-09
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 4
20
Bunkyō City, Hirakata-shi, Iruma-Gun, Kyoto, Matsumoto-shi, Miyazaki, Nagoya, Nara
2025-12-19
Active, closed
A Clinical Evaluation of AMJ-401
NCT07373353Ischemic Heart Disease (IHD)
Abbott Medical Devices
Not applicable
50
Toyoake, Tokyo, Kitakyushu, Shiwa-gun, Kamakura, Kawasaki, Miyazaki, Sakai
2025-12-17
Recruiting
AstraZeneca
Phase 2
435
Bunkyō City, Gifu, Hiratsuka-shi, Kamogawa-shi, Kiyose-shi, Kurashiki-shi, Meguro-ku, Miyazaki
2025-11-06
Recruiting
Pfizer
Phase 2
200
Takasaki, Yokohama, Sakai, Tachikawa, Miyazaki
2025-10-30
Active, closed
Merck Sharp & Dohme LLC
Phase 2
185
Hanishina-gun, Sasebo, Nagaoka, Tokorozawa, Chūō, Miyazaki
2025-10-08
Active, closed
Eli Lilly and Company
Phase 3
800
Fukuoka, Izumo, Kariya, Kawasaki, Minatoku, Miyazaki, Morioka, Saitama
2025-09-15
Recruiting
4D Molecular Therapeutics
Phase 3
480
Nagoya, Hyōgo, Fukushima, Mito, Miyazaki, Ginowan, Chiba, Fukuoka
2025-07-22
Active, closed
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
NCT06468033Primary Myelofibrosis, Myeloproliferative Neoplasm
DrugBesremi
PharmaEssentia
Phase 3
160
Kamogawa, Matsuyama, Hiroshima, Morioka, Kamakura, Tsu, Miyazaki, Hirakata
2025-07-18
Recruiting
Biogen
Phase 3
180
Chia-shi, Urayasu-Shi, Sapporo, Kita-Gun Uchiko-Cho, Sagamihara-Shi Minami-Ku, Yokohama, Miyazaki, Niigata
2025-05-22
Recruiting
AbbVie
Phase 2
150
Nagoya, Kashiwa-shi, Sapporo, Kobe, Sagamihara-shi, Sendai, Miyazaki, Kurashiki-shi
2025-01-20
Recruiting
National Cancer Center, Japan
Phase 2
38
Kashiwa, Kyoto, Miyazaki, Nagoya, Tokyo
2024-12-01
By invitation
Sanofi
Phase 2
900
Sakaidechō, Chūō, Ube, Fukushima, Kyoto, Miyazaki
2024-09-30
Recruiting
GlaxoSmithKline
Phase 3
440
Aichi, Fukuoka, Hiroshima, Hokkaido, Kanagawa, Miyagi, Miyazaki, Saitama
2024-09-11
Active, closed
Amgen
Phase 3
89
Fukuoka, Mito, Kanazawa, Miyazaki, Osaka-Shi Yodogawa-Ku
2024-07-05
Active, closed
Novo Nordisk A/S
Phase 3
10,000
Miyazaki, Aichi, Chiba, Ehime, Fukuoka, Fukuoka-shi, Fukuoka, Himeji-shi, Hyogo, Hokkaido
2024-06-25
Active, closed
Amgen
Phase 1/2
94
Nagakute-shi, Fukuoka, Mito, Miyazaki
2024-05-30
Recruiting
Otsuka Medical Devices Co., Ltd. Japan
Phase 1/2
49
Fukuoka, Sapporo, Kagoshima, Miyazaki, Nagasaki
2024-04-01
Active, closed
AbbVie
Phase 3
1,014
Kitakyushu-shi, Sapporo, Sendai, Miyazaki, Okayama, Naha, Kawagoe, Bunkyo-ku
2023-07-25
Recruiting
Janssen Research & Development, LLC
Phase 2/3
12
Azumino-shi, Chiba, Miyazaki, Nishinomiya-Shi, Saitama Shi, Shinjuku-ku
2022-07-20
Active, closed
Sun Pharmaceutical Industries Limited
Phase 3
529
Shinjuku-ku, Fukuoka, Itabashi-ku, Kumamoto, Mitaka, Miyazaki, Sendai, Tsu
2022-06-30
Active, closed
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
DrugsEylea·Aflibercept
AbbVie
Phase 3
735
Nagoya, Fukushima, Kobe, Nishinomiya-shi, Kagoshima, Kyoto, Miyazaki, Ōtsu
2022-01-13
Recruiting
Boston Scientific Corporation
Observational
5,000
Sapporo, Kyoto, Miyazaki, Aichi, Chiba, Osaka
2021-03-29
Active, closed
PharmaEssentia
Phase 3
174
Tōon, Sagamihara, Tsu, Miyazaki, Hirakata, Sayama, Suita, Izunokuni
2020-08-25
Active, closed
Sun Pharmaceutical Industries Limited
Phase 3
296
Nagoya, Kitakyushu, Sendai, Miyazaki, Mitaka, Shinjuku, tabashi City, Kitakyushu-shi
2020-07-01
Recruiting
Sumitomo Pharma America, Inc.
Phase 1/2
240
Aichi, Aomori, Chiba, Fukuoka, Hokkaido, Kamakura, Miyazaki, Okayama
2019-12-16
Active, closed
AstraZeneca
Phase 3
1,063
Bunkyō City, Fukuoka, Hirosaki-shi, Hiroshima, Kanazawa, Kōtoku, Kumamoto, Miyazaki
2018-11-16
Recruiting
REASSURE-NIRS Registry
NCT04864171Lipid-Rich Atherosclerosis of Coronary Artery
National Cerebral and Cardiovascular Center, Japan
Observational
2,000
Miyazaki, Suita
2018-10-09
Active, closed
Janssen Research & Development, LLC
Phase 3
629
Chiba, Hirosaki, Kashiwa, Kita Gun, Kobe, Koshigaya, Matsuyama, Miyazaki
2018-03-23
Active, closed
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
NCT03165734Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugPacritinib
Swedish Orphan Biovitrum
Phase 3
407
Chūō, Fukuoka, Fukushima, Miyagi, Miyazaki, Tokyo, Tōon, Tsu
2017-06-26
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,052
Chūōku, Hakata-Ku, Koshigaya, Matsuyama, Minamiku, Miyazaki, Nagano, Nagasaki
2015-11-27
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
982
Fukuoka, Kanazawa, Kashiwa, Kita-Gun, Kumamoto, Kurume, Matsuyama, Miyazaki
2014-11-26
Rows per page Showing 1–36 of 36
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/miyazaki

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 36 of those studies with a site in Miyazaki.

How many clinical trials are recruiting in Miyazaki?

18 of the 36 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 17 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Miyazaki), 36 studies
PhaseStudiesRecruitingShare
Phase 321758.3%
Phase 27519.4%
Phase 1/2328.3%
Observational225.6%
Not applicable102.8%
Phase 2/3112.8%
Phase 4112.8%

Most active sponsors

Lead sponsors with the most studies (Miyazaki)
Lead sponsorStudiesRecruiting
AstraZeneca43
AbbVie31
Amgen20
Aragon Pharmaceuticals, Inc.20
Eli Lilly and Company21
Janssen Research & Development, LLC21
PharmaEssentia20
Sun Pharmaceutical Industries Limited20
4D Molecular Therapeutics11
Abbott Medical Devices10
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.